Pre Eclampsia Pipeline Insight

DelveInsight’s, “Pre-Eclampsia – Pipeline Insight, 2022,” report provides comprehensive insights about companies and pipeline drugs in the Pre-Eclampsia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Pre-Eclampsia Understanding

Pre-Eclampsia : Overview

Pre-Eclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. Pre-Eclampsia is a combination of hypertension (raised blood pressure) and proteinuria in pregnancy (the presence of protein in your urine). It generally develops during the third trimester. The condition affects around 5% to 8% of pregnancies and presents serious health consequences to mothers and babies. There is not a single cause, but some potential causes include: genetic factors and blood vessel problems. Left untreated, Pre-Eclampsia can lead to serious — even fatal — complications for both mother and baby.


“Pre-Eclampsia – Pipeline Insight, 2022,” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pre-Eclampsia pipeline landscape is provided which includes the disease overview and Pre-Eclampsia treatment guidelines. The assessment part of the report embraces, in depth Pre-Eclampsia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pre-Eclampsia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Pre-Eclampsia Emerging Drugs Chapters

This segment of the Pre-Eclampsia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Pre-Eclampsia Emerging Drugs


KW3357: Kyowa Kirin Co., Ltd.

KW-3357 is an antithrombin (AT) drug created through the technology of recombinant DNA and sugar-chain control, which is a recombinant AT preparation with the same amino acid sequence and the same type of sugar chain structure as human natural AT. AT inhibits blood coagulation by forming a complex with the coagulation factor of proteolytic enzyme. In Japan, KW-3357 has been approved for the treatments of thrombophilia due to congenital AT deficiency (CAD) and disseminated intravascular coagulation (DIC) since July, 2015 and commercialized under the brand name of ACOALAN. KW3357 is currently in phase III stage of development by Kyowan Kirin Co.,Ltd in collaboration with Japan Blood Products Organization for Preeclampsia.


rhC1INH protein replacement therapy: Pharming Group

Pharming Group is developing a rhC1INH protein replacement therapy for the treatment of pre-eclampsia. Pre-eclampsia is a life-threatening multisystem disorder in pregnancies leading to maternal and neonatal mortality and morbidity, usually first appearing as hypertension and proteinuria. Pharming Group had initiated the therapy in 2019 and was in phase I/II of development, but was halted due to COVID-19.

Further product details are provided in the report……..

Pre-Eclampsia : Therapeutic Assessment

This segment of the report provides insights about the different Pre-Eclampsia drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Pre-Eclampsia

There are several companies which are developing the therapies for Pre-Eclampsia . The companies which have their Pre-Eclampsia drug candidates in the mid to advanced stage, i.e. phase III include, Kyowa Kirin Co.,Ltd. and others.

Phases

DelveInsight’s report covers products under different phases of clinical development like

  • Late-stage products (Phase III )
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Pre-Eclampsia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Replacement Therapy
  • Physiological Saline
  • Antihypertensive
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pre-Eclampsia : Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pre-Eclampsia therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pre-Eclampsia drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pre-Eclampsia R&D. The therapies under development are focused on novel approaches to treat/improve Pre-Eclampsia .

Pre-Eclampsia Report Insights

  • Pre-Eclampsia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Pre-Eclampsia Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Pre-Eclampsia drugs?
  • How many Pre-Eclampsia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pre-Eclampsia ?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pre-Eclampsia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Pre-Eclampsia and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Pre-Eclampsia : Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Pre-Eclampsia – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Pre-Eclampsia companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Pre-Eclampsia Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

KW 3357: Kyowa Kirin Co., Ltd.

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

  • Comparative Analysis

rhC1INH protein replacement therapy: Pharming Group

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Pre-Eclampsia Key Companies

Pre-Eclampsia Key Products

Pre-Eclampsia - Unmet Needs

Pre-Eclampsia - Market Drivers and Barriers

Pre-Eclampsia - Future Perspectives and Conclusion

Pre-Eclampsia Analyst Views

Pre-Eclampsia Key Companies

Appendix

List of Table

Table 1: Total Products for Pre-Eclampsia

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Pre-Eclampsia

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products      

• Kyowa Kirin Co., Ltd

• Pharming Group

• Amag Pharmaceuticals

• MirZyme

Forward to Friend

Need A Quote